Day Two
DAY ONE

Tuesday 06 November 2001
08.50 Chairman's Opening Remarks:
Prof. Dr. Horst Domdey, CEO, Bio-M AG
09.00 Bioethics and Political Developments in Europe
Dr. Eric Tambuyzer, Chairman EuropaBio Board of Management,
Vice President, Corporate Affairs Europe,
GENZYME Corporation
09.20 Overview of the IPO & Private Placement Market
Barbara Heller, First Vice President
Claudio Werder, First Vice President, Head of Life Sciences Team
Bank Vontobel AG
09.40 European Biotech & IPO
Robert Wyss, Head SWX New Market,
SWX Swiss Exchange
10.00 Value Considerations in Early Stage Biotech Ventures
Dr. Rudolf Gygax, Portfolio & Business Manager,
Novartis Venture Fund
10.20 The Evolving German Biotech Landscape
Dr. Jörg Neermann, Senior Partner,
DVC Deutsche Venture Capital
10.40 Reverse Takeovers: An Alternative to IPO's
Andreas Hoffmann, Partner, Baker & McKenzie
10.55

Break

11.15

SECTOR PANEL
Life Science Investment Opportunities
Chair: Dr. Juerg Meier, Novartis Venture Fund

Dr. Alexandra Goll, Partner, TVM Techno Venture Management
Models and Reality Check

Prof. Dr. Kai Deusch, Director, Apax Partners
Is Biotech a B2B Marketplace?

Graham Boulnois, Schroder Ventures Life Sciences
Venture Financing

Dr. Holger N. Mueller, Investment Director, 3i Deutschland
Capturing the Value of Knowledge Generated in Biotech Companies

12.30

ACADEMIC KEYNOTE
Professor Stephen K. Smith, Head of Department, Obstetrics & Gynaecology, University of Cambridge
Science-based Developments in Women's Health
11.15-15.40
BREAK OUT SESSION		 Listed and Pre-IPO Company Presentations
12.55 Lunch
14.15

Partnering Models for Pharmaceutical & Biotechnology Companies
Kerry Clough, GlaxoSmithKline
14.35

VENTURE FINANCE PANEL
Chair: Dr. Hans A Küpper, Managing Director
Life Science Ventures GmbH
Growth Strategies & Business Models

Robert Zegelaar, Principal, Atlas Venture

Nick Lowcock, Managing Director, European Healthcare,
E.M Warburg, Pincus & Co. International, Ltd.

Philip Rattle, Director, JPMorgan Partners

Dr. Fredrik Buch, Partner, HealthCap

15.40-18.30 STREAMED COMPANY PRESENTATION WORKSHOPS
Featuring up to 30 Start-Up – Pre-IPO Companies

Post-Genomics: PharmacoGenomics & Proteomics

Immunology / Oncology

Therapeutics

 

Tea / Coffee

 

Medical Devices,
Diagnostics

Biomedical Engineering & Bio Materials

Bioinformatics, SNP,
Arrray Technology
18.30 COCKTAIL RECEPTION
DAY TWO Wednesday 07 November 2001
08.50 Chairman’s Opening Remarks:
Stan Yakatan, Chairman,
Katan Associates
09.00

GLOBAL DEVELOPMENT PANEL
Germany / Scandinavia / Israel / UK / Switzerland

Dr. Jens A Katzek, Managing Director, German Association of Biotechnology Industries (DIB)

Dr. Jeff Solomon, Chief Executive, ERBI, UK

Prof. Dr. Jesper Zeuthen, Managing Director, BankInvest Bio Venture

Mr. Otello Stampacchia, Vice President of Immunology,
Lombard Odier & Cie

Dr. Dalia Megiddo, MBA, Managing Partner of Innomed Ventures,
Jerusalem Global Ventures – Innomed

10.20 Break
10.40

STREAMED COMPANY PRESENTATION WORKSHOPS (continued)
Featuring up to 24 Start-Up – Pre-IPO Companies
13.30-15.30 Conclusion of Conference and Networking Lunch
back to top